|
Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval
|
Written by: J. Smith |
Hits: 884
|
|
Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race
|
Written by: J. Smith |
Hits: 458
|
|
FDA and Novo Nordisk Warn of Counterfeit Ozempic in U.S. Supply Chain
|
Written by: J. Smith |
Hits: 502
|
|
Liraglutide Reduces BMI in Children Under 12 With Obesity, But Questions Remain
|
Written by: J. Smith |
Hits: 399
|
|
Dexcom G7 15-Day CGM Wins FDA Clearance
|
Written by: J. Smith |
Hits: 888
|
|
Rybelsus® Cuts Cardiovascular Risk by 14% in SOUL Trial
|
Written by: J. Smith |
Hits: 687
|
|
Ozempic® Shows New Benefit for People with Type 2 Diabetes and PAD
|
Written by: J. Smith |
Hits: 1005
|
|
Novo Nordisk Strikes $2 Billion Deal for Potential Rival to Lilly’s Triple Agonist Drug
|
Written by: J. Smith |
Hits: 574
|
|
Novo Nordisk Expands $499 Wegovy® Offer to Retail Pharmacies
|
Written by: J. Smith |
Hits: 475
|
|
Dexcom Receives FDA Warning Letter Over Manufacturing Issues
|
Written by: J. Smith |
Hits: 926
|
